NATO chief underlines importance of full implementation of Minsk agreementsWorld May 25, 12:07
170 homes burn down in Siberian fires, Russian Emergencies Ministry saysWorld May 25, 11:52
Russia starts state trials of upgraded ‘Night Hunter’ helicopterMilitary & Defense May 25, 11:41
Stoltenberg says Norway remembers Red Army’s role in liberation from fascismWorld May 25, 11:16
Stoltenberg welcomes contacts between NATO-allied countries and RussiaWorld May 25, 10:51
Soyuz carrier rocket with military satellite launched from Russian spaceportScience & Space May 25, 10:07
Envoy slams US intel brass’ claims on Russia’s intrusion into EU polls as ‘nonsense’Russian Politics & Diplomacy May 25, 9:16
Russia moves Iskander missile systems for drills to Tajikistan for first timeMilitary & Defense May 25, 8:40
Soviet 'worker and peasant girl' statue for 1937 World's Fair marks 80th anniversarySociety & Culture May 25, 8:15
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.